Maria Passerini

A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study

A. Berra, J. Tau, Maria Passerini, 2022, Graefe's Archive for Clinical and Experimental Ophthalmology.

Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial

D. Grigera, Maria Passerini, J. Casiraghi, 2021, Re:GEN Open.

Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day for cataract postsurgical inflammation treatment: noninferiority trial

R. Zaldívar, Myriam Nuñez, V. Ferroni, 2021, Journal of cataract and refractive surgery.

Clinical and physiopathological aspects of the glossopharyngeal neuralgia

Maria Passerini, Hilton Junior, Victor Souza, 2021, Headache Medicine.

Evaluation of the osmoprotective and bioprotective effect of trehalose 3%

María Ximena Guerbi, Maria Passerini, Victor Sendra, 2023, The Pan-American Journal of Ophthalmology.

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis

Maria Passerini, Paula Albera, Melina Sol Del Papa, 2023, Clinical ophthalmology.

Hyaluronate Protects From Benzalkonium Chloride-Induced Ocular Surface Toxicity

F. Sabbione, J. Galletti, Alexia Vereertbrugghen, 2024, Translational vision science & technology.